RU2704008C2 - Гетероциклические соединения и их применение - Google Patents
Гетероциклические соединения и их применение Download PDFInfo
- Publication number
- RU2704008C2 RU2704008C2 RU2017109355A RU2017109355A RU2704008C2 RU 2704008 C2 RU2704008 C2 RU 2704008C2 RU 2017109355 A RU2017109355 A RU 2017109355A RU 2017109355 A RU2017109355 A RU 2017109355A RU 2704008 C2 RU2704008 C2 RU 2704008C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- alkyl
- atom
- nitrogen
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053389P | 2014-09-22 | 2014-09-22 | |
| US62/053,389 | 2014-09-22 | ||
| PCT/US2015/051143 WO2016048861A2 (en) | 2014-09-22 | 2015-09-21 | Heterocyclic compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017109355A RU2017109355A (ru) | 2018-10-24 |
| RU2017109355A3 RU2017109355A3 (enExample) | 2019-04-04 |
| RU2704008C2 true RU2704008C2 (ru) | 2019-10-23 |
Family
ID=55525127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017109355A RU2704008C2 (ru) | 2014-09-22 | 2015-09-21 | Гетероциклические соединения и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9862703B2 (enExample) |
| EP (1) | EP3197885B1 (enExample) |
| JP (1) | JP6615207B2 (enExample) |
| KR (1) | KR102509431B1 (enExample) |
| CN (1) | CN107207465B (enExample) |
| AU (1) | AU2015321654B2 (enExample) |
| BR (1) | BR112017005713B1 (enExample) |
| CA (1) | CA2962329C (enExample) |
| ES (1) | ES2849998T3 (enExample) |
| RU (1) | RU2704008C2 (enExample) |
| TW (1) | TWI598348B (enExample) |
| WO (1) | WO2016048861A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018208366B2 (en) * | 2017-01-10 | 2020-12-17 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| EA202090595A1 (ru) * | 2017-09-08 | 2020-06-29 | Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити | Ингибиторы enpp1 и способы модуляции иммунного ответа |
| EP3842435A4 (en) | 2018-09-20 | 2022-05-11 | Hanmi Pharm. Co., Ltd. | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE FRAMEWORK WITH INHIBITING ACTIVITY ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS |
| MX2021009269A (es) * | 2019-02-01 | 2021-08-24 | Univ Leland Stanford Junior | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. |
| CN111961034A (zh) | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| CN111138417B (zh) * | 2019-12-18 | 2021-03-23 | 浙江工业大学 | 一种三氮唑修饰的5-氟-2,4-嘧啶二胺类化合物及其应用 |
| WO2023014611A1 (en) * | 2021-08-02 | 2023-02-09 | Yeh, Teng-Kuang | Pyrimidine compounds and use thereof |
| KR20250093507A (ko) * | 2022-11-07 | 2025-06-24 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 퀴나졸린 유도체 |
| TW202435887A (zh) | 2023-03-01 | 2024-09-16 | 瑞士商諾華公司 | 用於治療疾病或障礙的氫喹唑啉衍生物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020078A1 (en) * | 1992-04-03 | 1993-10-14 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| WO2008005538A2 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| WO2009123221A1 (ja) * | 2008-03-31 | 2009-10-08 | 全薬工業株式会社 | 細胞保護作用を有するピリミジン誘導体およびその用途 |
| WO2014074517A1 (en) * | 2012-11-08 | 2014-05-15 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4936700A (enExample) * | 1972-08-16 | 1974-04-05 | ||
| KR20110005819A (ko) * | 2008-03-28 | 2011-01-19 | 알티리스 쎄라퓨틱스 | 케모카인 수용체 조절제 |
| AU2008355098B2 (en) | 2008-04-21 | 2012-11-15 | Gpcr Therapeutics, Inc | Heterocyclic compounds |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| US9951335B2 (en) | 2012-04-10 | 2018-04-24 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD |
| MX386924B (es) | 2012-10-10 | 2025-03-19 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades. |
-
2015
- 2015-09-21 CA CA2962329A patent/CA2962329C/en active Active
- 2015-09-21 ES ES15844487T patent/ES2849998T3/es active Active
- 2015-09-21 JP JP2017535616A patent/JP6615207B2/ja active Active
- 2015-09-21 BR BR112017005713-1A patent/BR112017005713B1/pt active IP Right Grant
- 2015-09-21 WO PCT/US2015/051143 patent/WO2016048861A2/en not_active Ceased
- 2015-09-21 KR KR1020177010762A patent/KR102509431B1/ko active Active
- 2015-09-21 AU AU2015321654A patent/AU2015321654B2/en active Active
- 2015-09-21 CN CN201580050829.5A patent/CN107207465B/zh active Active
- 2015-09-21 RU RU2017109355A patent/RU2704008C2/ru active
- 2015-09-21 US US14/860,033 patent/US9862703B2/en active Active
- 2015-09-21 EP EP15844487.7A patent/EP3197885B1/en active Active
- 2015-09-22 TW TW104131241A patent/TWI598348B/zh active
-
2017
- 2017-09-22 US US15/712,978 patent/US9926298B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020078A1 (en) * | 1992-04-03 | 1993-10-14 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| RU2103272C1 (ru) * | 1992-04-03 | 1998-01-27 | Дзе Апджон Компани | Бициклические гетероциклические амины и их фармацевтически приемлемые соли, бициклические гетероциклические амины и их фармацевтически приемлемые соли в качестве ингибитора реакционноспособного кислорода |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| WO2008005538A2 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| WO2009123221A1 (ja) * | 2008-03-31 | 2009-10-08 | 全薬工業株式会社 | 細胞保護作用を有するピリミジン誘導体およびその用途 |
| US8563715B2 (en) * | 2008-03-31 | 2013-10-22 | Zenyaku Kogyo Kabushikikaisha | Pyrimidine derivative having cell protecting effect and uses thereof |
| WO2014074517A1 (en) * | 2012-11-08 | 2014-05-15 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
Non-Patent Citations (5)
| Title |
|---|
| Brill W K-D, Riva-Toniolo C. Solid-phase synthesis of 2,6,8-trisubstituted purines, Tetrahedron Let, 2001, Vol:42, Nr:37, Page(s): 6515 6518. ПОПОВА Л.М. и др. Синтез и свойства 2,4-дизамещенных 6-фторпиримидинов, Журнал органической химии, 1996, т.32, 9, стр. 1424-1428. * |
| Chien -Huang WU et al. Stem Cell Mobilizers Targeting Chemokine Receptor CXCR4: Renoprotective Application in Acute Kidney Injury, Journal of Medicinal Chemistry, 16.02.2015, v.58, No.5, pp.2315-2325. * |
| DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; * |
| SAWADA G. A. ET AL. INCREASED LIPOPHILICITY AND SUBSEQUENT CELL PARTITIONING DECREASE PASSIVE TRANSCELLULAR DIFFUSION OF NOVEL, HIGHLY LIPOPHILIC ANTIOXIDANTS, JOURNAL OF * |
| SAWADA G. A. ET AL. INCREASED LIPOPHILICITY AND SUBSEQUENT CELL PARTITIONING DECREASE PASSIVE TRANSCELLULAR DIFFUSION OF NOVEL, HIGHLY LIPOPHILIC ANTIOXIDANTS, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, Vol:288, Nr:3, Page(s): 1317-1326. * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201615637A (zh) | 2016-05-01 |
| ES2849998T3 (es) | 2021-08-24 |
| RU2017109355A (ru) | 2018-10-24 |
| EP3197885A2 (en) | 2017-08-02 |
| CA2962329A1 (en) | 2016-03-31 |
| BR112017005713A2 (pt) | 2018-01-23 |
| AU2015321654B2 (en) | 2019-10-31 |
| EP3197885A4 (en) | 2018-02-21 |
| JP6615207B2 (ja) | 2019-12-04 |
| AU2015321654A1 (en) | 2017-04-06 |
| NZ730195A (en) | 2023-12-22 |
| US20160083369A1 (en) | 2016-03-24 |
| TWI598348B (zh) | 2017-09-11 |
| JP2017530193A (ja) | 2017-10-12 |
| WO2016048861A3 (en) | 2016-09-15 |
| CA2962329C (en) | 2023-12-19 |
| CN107207465B (zh) | 2021-09-10 |
| EP3197885B1 (en) | 2020-11-18 |
| US20180009786A1 (en) | 2018-01-11 |
| US9926298B2 (en) | 2018-03-27 |
| CN107207465A (zh) | 2017-09-26 |
| WO2016048861A2 (en) | 2016-03-31 |
| US9862703B2 (en) | 2018-01-09 |
| BR112017005713B1 (pt) | 2023-09-26 |
| RU2017109355A3 (enExample) | 2019-04-04 |
| KR20170072894A (ko) | 2017-06-27 |
| KR102509431B1 (ko) | 2023-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9926298B2 (en) | Heterocyclic compounds and use thereof | |
| JP6186125B2 (ja) | 疼痛の研究、画像化および治療方法、ならびに疼痛の研究、画像化および治療のための組成物 | |
| DE60016454T2 (de) | Triazaspiro[5.5]undecanderivate und Drogen, die dasselbe als aktiven Inhaltsstoff enthalten | |
| JP4808380B2 (ja) | Ｈｉｖプロテアーゼ阻害剤としてのカルバミン酸エステル | |
| CN103827108B (zh) | 丙型肝炎病毒抑制剂 | |
| TW202519515A (zh) | 蛋白酪胺酸磷酸酶抑制劑及其使用方法 | |
| KR20140059167A (ko) | Ｉｄｏ 억제제로서 유용한 융합된 이미다졸 유도체 | |
| JP2012504632A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| RS57108B1 (sr) | Derivati izoindolina za upotrebu u lečenju virusne infekcije | |
| EA019289B1 (ru) | Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина | |
| JP6196678B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| RU2756055C2 (ru) | Гетероциклические соединения и их применение | |
| JP6673932B2 (ja) | インドール及びアザインドール誘導体、並びに神経変性疾患におけるそれらの使用 | |
| HK1238644A1 (en) | Heterocyclic compounds and use thereof | |
| HK1238644B (en) | Heterocyclic compounds and use thereof | |
| WO2025202931A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| EA050362B1 (ru) | Соединения и их применения | |
| HK40010586A (en) | Heterocyclic compounds and use thereof | |
| BR112019013493B1 (pt) | Compostos heterocíclicos e seus usos, composição farmacêutica e método de mobilização de células-tronco hematopoiéticas e células progenitoras endoteliais na circulação periférica | |
| CN107011344A (zh) | 用于研究、成像以及治疗疼痛的方法和组合物 |